White Paper: Evaluating Emerging Tobacco Products ….
Decades of studies have conclusively demonstrated that smoking combustible cigarettes, as well as second-hand smoke, are major causes of global morbidity and mortality from a constellation of conditions, including but not limited to chronic disorders such as pulmonary and cardiovascular disease, and multiple types of cancer.1 The most effective approach to harm reduction is smoking cessation. However, the addictive nature of nicotine and the behavioral aspects of smoking make this a challenging process. There is therefore a significant need to develop and regulate products such as e-cigarettes, that could potentially serve as reduced-risk alternatives.
Fact Sheet: Clinical & Biometrics
Frontage’s clinical teams have set new standards for rapid start-up and efficient study conduct. Our experienced staff provides study management services for all phases of clinical research, including study design, protocol and ICF development, IRB submission, study execution, data management, pharmacokinetic/pharmacodynamic analysis, programming, biostatistics, and medical writing, to take each study from start to finish.
Poster: ADC PK Profiling Strategies on LC-MS Platforms: Top-down, Bottom-up…
With more monoclonal antibody (mAb) drug conjugates (ADC’s) under preclinical development and in clinical studies, comprehensive and reliable pharmacokinetic evaluation of ADC moieties is increasingly demanded. Liquid chromatography coupled to mass spectrometry (LC-MS) methods have served as sensitive, selective, and versatile tools for ADC PK profiling. Presented here are ADC LC-MS methodology approaches used at Frontage.
Brochure: Frontage Laboratories Company Overview
Frontage Laboratories, Inc. is a CRO providing integrated, scientifically-driven research, analytical and development services. With over 17 years of experience, we have successfully assisted our clients in advancing hundreds of compounds through the drug development process.
Fact Sheet: CMC Product Development
Frontage’s CMC portfolio of services spans drug product development, analysis, delivery and supply, from proof-of-concept, preclinical stages through Phase III clinical trials and commercialization support. With proven success in developing drug products for novel, generic and consumer products, we focus our efforts on clients’ specific needs. Our formulation development experience and capabilities cover a wide range of dosage forms at IND, NDA, ANDA and 505(b)(2) project stages and applications.